Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses current and emerging therapies for alopecia areata, highlighting unmet therapeutic needs and the psychosocial burden on patients but reports no new clinical results.

In this study, a case of a Spitz dog with refractory dermatophytosis demonstrated marked clinical improvement and complete cure with Posaconazole, highlighting the potential of antifungal susceptibility testing to guide effective treatment in persistent infections unresponsive to standard therapies.

This study highlights the use of dermatoscopy as a valuable tool for diagnosing and monitoring alopecia areata, noting that specific hair shaft alterations such as exclamation-mark hairs and black dots are indicators of active disease, while vellus hairs signal early regrowth.

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

Cortisone may help hair regrow by altering the local environment, with regrowth starting 3-4 weeks after treatment, but its use is not widely recommended.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This case report suggests that discontinuing finasteride, which may affect neurosteroids synthesis, improved seizure control in a woman with temporal lobe seizures.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This case study reports that ciclosporin effectively managed symptoms in a patient with steroid-dependent sudden sensorineural hearing loss, allowing discontinuation of corticosteroids and confirming remission through audiometry.

This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.

This case study reports that a police dog's pododemodicosis lesions resolved completely six months after a treatment regimen of ivermectin, antibacterial drugs, and beta-glucan.

This study hypothesized that finasteride administration may increase stress-induced amphetamine locomotor sensitization due to its impact on brain reward systems involving the neurosteroid allopregnanolone.

This study investigated the development of a polyherbal cosmeceutical serum containing extracts from five herbal drugs as a potentially safer treatment for alopecia areata, assessing its properties and stability.

This review article discusses recent advances in stem cell-based therapies for Alopecia Areata, noting preliminary clinical trials show significant hair regrowth, but emphasizes the need for thorough evaluation of long-term safety and efficacy.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

This study evaluated two cases of individualised homoeopathic treatment for alopecia areata and found that Phosphorus treatment resulted in complete hair regrowth and symptom resolution over 18 months.

This presentation explored recent developments in treating alcohol, opioid, and cannabis addiction, highlighting promising pharmacological and behavioral therapies, such as extended-release naltrexone for alcohol use and long-acting buprenorphine for opioids, alongside emerging strategies for cannabis use disorder.

This study found that pulse corticosteroids effectively induce hair regrowth in alopecia areata, with betamethasone showing higher efficacy but more side effects, and treatment success varying depending on age, onset time, and disease type.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

This review discusses recent advancements in behavioral and pharmacological treatments for trichotillomania but does not report new clinical results, emphasizing the need for rigorous future research.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This study produced a guide for managing adult female acne, addressing its complex nature compared to teenage acne, and providing detailed recommendations on diagnosis and treatment. The authors noted that further research is needed to better understand the condition.

This article reviews lichen planopilaris, its presentation, and treatment challenges, and emphasizes the need for more research into its pathogenesis and therapy efficacy; it reports no new findings.

This study suggests that oral budesonide may not effectively maintain remission in Crohn's disease beyond three months, with minor benefits that are outweighed by increased rates of treatment-related adverse events.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This review suggests that melasma may be a photoaging skin disorder affecting genetically predisposed individuals, which could significantly influence its treatment and prevention strategies.

This review discusses various treatments for alopecia areata, highlighting their limitations and individualized approach, and reports no new clinical results.

In this study, complete to excellent hair regrowth was observed in 63.3% of patients with extensive alopecia areata treated with biweekly dexamethasone pulses, although mild side effects were frequent.

This review discusses progress in targeted therapies for vitiligo, focusing on Janus kinase inhibitors and the potential of mesenchymal stem cells, but reports no new clinical results.